Erratum: Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study (The Lancet (2016) 388(10061) (2763–2774) (S0140673616316518) (10.1016/S0140-6736(16)31651-8));Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study

The Lancet

Volumn 388, Issue 10061, 2016, Pages 2763-2774

  Smolen, Josef S ^a   Burmester, Gerd Rüdiger ^b   Combe, Bernard ^c   Curtis, Jeffrey R ^d   Hall, Stephen ^e   Haraoui, Boulos ^f   van Vollenhoven, Ronald ^g   Cioffi, Christopher ^h   Ecoffet, Cécile ^h   Gervitz, Leon ^h   Ionescu, Lucian ^h   Peterson, Luke ^h   Fleischmann, Roy ⁱ  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c MONTPELLIER UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e MONASH UNIVERSITY   (Australia)

^f CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^g Amsterdam Rheumatology and Immunology Center   (Netherlands)

^h UCB PHARMA   (Belgium)

ⁱ UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; METHOTREXATE; PLACEBO; RHEUMATOID FACTOR; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; ASPERGILLOSIS; CANDIDIASIS; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DAS28; DISEASE COURSE; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HEART INFARCTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MILIARY TUBERCULOSIS; MULTIPLE CYCLE TREATMENT; MYCOBACTERIOSIS; NON SMALL CELL LUNG CANCER; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCREENING TEST; SINGLE BLIND PROCEDURE; TREATMENT DURATION; TREATMENT RESPONSE; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL;

ADALIMUMAB; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CERTOLIZUMAB PEGOL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; SINGLE-BLIND METHOD;

EID: 85003681006     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)32426-6     Document Type: Erratum

References (33)

1. 1 Smolen, JS, Aletaha, D, McInnes, IB, Rheumatoid arthritis. Lancet, 2016, 10.1016/S0140-6736(16)30173-8 published online May 3.
2. 2 Gibofsky, A, Current therapeutic agents and treatment paradigms for the management of rheumatoid arthritis. Am J Manag Care 20 (2014), S136–S144.
3. 3 Singh, JA, Saag, KG, Bridges, SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol 68 (2016), 1–26.
4. 4 Smolen, JS, Landewe, R, Breedveld, FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73 (2014), 492–509.
5. 5 Schiff, M, Weinblatt, ME, Valente, R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis 73 (2014), 86–94.
6. 6 Porter, D, van Melckebeke, J, Dale, J, et al. Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. Lancet 388 (2016), 239–247.
7. 7 Buckley, F, Finckh, A, Huizinga, TW, Dejonckheere, F, Jansen, JP, Comparative efficacy of novel dmards as monotherapy and in combination with methotrexate in rheumatoid arthritis patients with inadequate response to conventional DMARDs: a network meta-analysis. J Manag Care Spec Pharm 21 (2015), 409–423.
8. 8 Aletaha, D, Alasti, F, Smolen, JS, Optimisation of a treat-to-target approach in rheumatoid arthritis: strategies for the 3-month time point. Ann Rheum Dis 75 (2016), 1479–1485.
9. 9 Song, F, Loke, YK, Walsh, T, Glenny, AM, Eastwood, AJ, Altman, DG, Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews. BMJ, 338, 2009, b1147.
10. 10 Fleischmann, R, Landewe, R, Smolen, J, Review of head-to-head study designs in rheumatoid arthritis. Semin Arthritis Rheum, 2016 in press.
11. 11 Cipriani, A, Higgins, JP, Geddes, JR, Salanti, G, Conceptual and technical challenges in network meta-analysis. Ann Intern Med 159 (2013), 130–137.
12. 12 Aletaha, D, Funovits, J, Keystone, EC, Smolen, JS, Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum 56 (2007), 3226–3235.
13. 13 Smolen, JS, Breedveld, FC, Burmester, GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 75 (2016), 3–15.
14. 14 Weinblatt, ME, Fleischmann, R, Huizinga, TW, et al. Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. Rheumatology 51 (2012), 2204–2214.
15. 15 Smolen, JS, Kay, J, Doyle, MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 374 (2009), 210–221.
16. 16 Goel, N, Stephens, S, Certolizumab pegol. MAbs 2 (2010), 137–147.
17. 17 Aletaha, D, Neogi, T, Silman, AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69 (2010), 1580–1588.
18. 18 Emery, P, Bingham, CO 3rd, Burmester, GR, et al. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naive patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study. Ann Rheum Dis, 2016, 10.1136/annrheumdis-2015-209057 published online May 10.
19. 19 Furst, DE, Schiff, MH, Fleischmann, RM, et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatology 30 (2003), 2563–2571.
20. 20 Smolen, J, Landewe, RB, Mease, P, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 68 (2009), 797–804.
21. 21 Keystone, E, Heijde, D, Mason, D Jr, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 58 (2008), 3319–3329.
22. 22 Hochberg, Y, Benjamini, Y, More powerful procedures for multiple significance testing. Stat Med 9 (1990), 811–818.
23. 23 Krishnan, E, Sokka, T, Hakkinen, A, Hubert, H, Hannonen, P, Normative values for the Health Assessment Questionnaire disability index: benchmarking disability in the general population. Arthritis Rheum 50 (2004), 953–960.
24. 24 Genovese, MC, Becker, JC, Schiff, M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 353 (2005), 1114–1123.
25. 25 Cohen, SB, Emery, P, Greenwald, MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54 (2006), 2793–2806.
26. 26 Emery, P, Keystone, E, Tony, HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 67 (2008), 1516–1523.
27. 27 Emery, P, Gottenberg, JE, Rubbert-Roth, A, et al. Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study. Ann Rheum Dis 74 (2015), 979–984.
28. 28 Rubbert-Roth, A, Finckh, A, Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther, 11, 2009, S1.
29. 29 Day, SJ, Altman, DG, Statistics notes: blinding in clinical trials and other studies. BMJ, 321, 2000, 504.
30. 30 Edejer, T-T, Baltussen, R, Adam, T, et al. WHO guide to cost-effectiveness analysis, 2003, World Health Organization, Geneva.
31. 31 Guyatt, GH, Oxman, AD, Kunz, R, et al. Incorporating considerations of resources use into grading recommendations. BMJ 336 (2008), 1170–1173.
32. 32 Holloway, K, van Dijk, L, The World Medicines Situation 2011. Rational use of medicines, 2011, World Health Organization, Geneva.
33. 33 Putrik, P, Ramiro, S, Kvien, TK, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis 73 (2014), 198–206.